vs
ICU MEDICAL INC（ICUI）与SSR MINING INC.（SSRM）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是SSR MINING INC.的1.0倍（$540.7M vs $521.7M），SSR MINING INC.净利率更高（34.8% vs -2.9%，领先37.7%），SSR MINING INC.同比增速更快（61.4% vs -14.1%），SSR MINING INC.自由现金流更多（$106.4M vs $36.0M），过去两年SSR MINING INC.的营收复合增速更高（50.5% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
SSR Mining Inc.（前身为白银标准资源公司）总部位于美国科罗拉多州丹佛，主营金、银、铜、铅、锌矿产开采，拥有阿根廷最大的银矿，同时在美洲全境及土耳其开展矿产勘探业务。2020年与阿拉瑟黄金合并后迁至丹佛，现任总裁兼首席执行官为罗德尼·P·安塔尔。
ICUI vs SSRM — 直观对比
营收规模更大
ICUI
是对方的1.0倍
$521.7M
营收增速更快
SSRM
高出75.6%
-14.1%
净利率更高
SSRM
高出37.7%
-2.9%
自由现金流更多
SSRM
多$70.4M
$36.0M
两年增速更快
SSRM
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $521.7M |
| 净利润 | $-15.7M | $181.5M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 38.8% |
| 净利率 | -2.9% | 34.8% |
| 营收同比 | -14.1% | 61.4% |
| 净利润同比 | 34.0% | 3166.6% |
| 每股收益（稀释后） | $-0.63 | $0.84 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUISSRM
| Q4 25 | $540.7M | $521.7M | ||
| Q3 25 | $537.0M | $385.8M | ||
| Q2 25 | $548.9M | $405.5M | ||
| Q1 25 | $604.7M | $316.6M | ||
| Q4 24 | $629.8M | $323.2M | ||
| Q3 24 | $589.1M | $257.4M | ||
| Q2 24 | $596.5M | $184.8M | ||
| Q1 24 | $566.7M | $230.2M |
净利润ICUISSRM
| Q4 25 | $-15.7M | $181.5M | ||
| Q3 25 | $-3.4M | $65.4M | ||
| Q2 25 | $35.3M | $90.1M | ||
| Q1 25 | $-15.5M | $58.8M | ||
| Q4 24 | $-23.8M | $5.6M | ||
| Q3 24 | $-33.0M | $10.6M | ||
| Q2 24 | $-21.4M | $9.7M | ||
| Q1 24 | $-39.5M | $-287.1M |
毛利率ICUISSRM
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
营业利润率ICUISSRM
| Q4 25 | 1.0% | 38.8% | ||
| Q3 25 | 2.6% | 21.6% | ||
| Q2 25 | 1.9% | 26.9% | ||
| Q1 25 | 2.1% | 21.1% | ||
| Q4 24 | 6.0% | 10.6% | ||
| Q3 24 | 1.4% | 3.5% | ||
| Q2 24 | 1.3% | 5.8% | ||
| Q1 24 | -1.9% | -163.5% |
净利率ICUISSRM
| Q4 25 | -2.9% | 34.8% | ||
| Q3 25 | -0.6% | 17.0% | ||
| Q2 25 | 6.4% | 22.2% | ||
| Q1 25 | -2.6% | 18.6% | ||
| Q4 24 | -3.8% | 1.7% | ||
| Q3 24 | -5.6% | 4.1% | ||
| Q2 24 | -3.6% | 5.2% | ||
| Q1 24 | -7.0% | -124.7% |
每股收益（稀释后）ICUISSRM
| Q4 25 | $-0.63 | $0.84 | ||
| Q3 25 | $-0.14 | $0.31 | ||
| Q2 25 | $1.43 | $0.42 | ||
| Q1 25 | $-0.63 | $0.28 | ||
| Q4 24 | $-0.97 | $0.03 | ||
| Q3 24 | $-1.35 | $0.05 | ||
| Q2 24 | $-0.88 | $0.05 | ||
| Q1 24 | $-1.63 | $-1.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $575.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $3.5B |
| 总资产 | $4.1B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUISSRM
| Q4 25 | — | $575.6M | ||
| Q3 25 | — | $445.4M | ||
| Q2 25 | — | $438.5M | ||
| Q1 25 | — | $341.3M | ||
| Q4 24 | $308.6M | $417.3M | ||
| Q3 24 | $312.5M | $365.8M | ||
| Q2 24 | $302.6M | $384.4M | ||
| Q1 24 | $251.4M | $492.0M |
总债务ICUISSRM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $228.6M | ||
| Q3 24 | — | $228.3M | ||
| Q2 24 | — | $228.0M | ||
| Q1 24 | — | $228.7M |
股东权益ICUISSRM
| Q4 25 | $2.1B | $3.5B | ||
| Q3 25 | $2.1B | $3.3B | ||
| Q2 25 | $2.1B | $3.3B | ||
| Q1 25 | $2.0B | $3.2B | ||
| Q4 24 | $2.0B | $3.1B | ||
| Q3 24 | $2.0B | $3.1B | ||
| Q2 24 | $2.0B | $3.1B | ||
| Q1 24 | $2.1B | $3.1B |
总资产ICUISSRM
| Q4 25 | $4.1B | $6.1B | ||
| Q3 25 | $4.1B | $5.9B | ||
| Q2 25 | $4.1B | $5.8B | ||
| Q1 25 | $4.2B | $5.6B | ||
| Q4 24 | $4.2B | $5.2B | ||
| Q3 24 | $4.3B | $5.1B | ||
| Q2 24 | $4.3B | $5.2B | ||
| Q1 24 | $4.3B | $5.3B |
负债/权益比ICUISSRM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× | ||
| Q1 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $172.1M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $106.4M |
| 自由现金流率自由现金流/营收 | 6.6% | 20.4% |
| 资本支出强度资本支出/营收 | 4.6% | 12.6% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $241.6M |
8季度趋势，按日历期对齐
经营现金流ICUISSRM
| Q4 25 | $60.6M | $172.1M | ||
| Q3 25 | $56.7M | $57.2M | ||
| Q2 25 | $11.2M | $157.8M | ||
| Q1 25 | $51.3M | $84.8M | ||
| Q4 24 | $40.2M | $95.0M | ||
| Q3 24 | $36.1M | $-1.3M | ||
| Q2 24 | $82.0M | $-78.1M | ||
| Q1 24 | $45.8M | $24.6M |
自由现金流ICUISSRM
| Q4 25 | $36.0M | $106.4M | ||
| Q3 25 | $27.6M | $-2.4M | ||
| Q2 25 | $-8.5M | $98.4M | ||
| Q1 25 | $36.7M | $39.3M | ||
| Q4 24 | $16.1M | $56.4M | ||
| Q3 24 | $16.2M | $-34.1M | ||
| Q2 24 | $62.5M | $-116.3M | ||
| Q1 24 | $29.9M | $-9.4M |
自由现金流率ICUISSRM
| Q4 25 | 6.6% | 20.4% | ||
| Q3 25 | 5.1% | -0.6% | ||
| Q2 25 | -1.5% | 24.3% | ||
| Q1 25 | 6.1% | 12.4% | ||
| Q4 24 | 2.6% | 17.5% | ||
| Q3 24 | 2.7% | -13.2% | ||
| Q2 24 | 10.5% | -62.9% | ||
| Q1 24 | 5.3% | -4.1% |
资本支出强度ICUISSRM
| Q4 25 | 4.6% | 12.6% | ||
| Q3 25 | 5.4% | 15.4% | ||
| Q2 25 | 3.6% | 14.7% | ||
| Q1 25 | 2.4% | 14.4% | ||
| Q4 24 | 3.8% | 11.9% | ||
| Q3 24 | 3.4% | 12.7% | ||
| Q2 24 | 3.3% | 20.7% | ||
| Q1 24 | 2.8% | 14.8% |
现金转化率ICUISSRM
| Q4 25 | — | 0.95× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | 0.32× | 1.75× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | 17.10× | ||
| Q3 24 | — | -0.13× | ||
| Q2 24 | — | -8.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
SSRM
| Gold | $369.3M | 71% |
| Concentrate Sales | $124.4M | 24% |
| Other | $19.1M | 4% |
| Lead | $9.0M | 2% |
